DJ‑1 is a new prognostic marker and predicts chemotherapy efficacy in colorectal cancer

Wang, Weimin; Wang, Haibo; Xiang, Lei; Ni, Tengyang; Jin, Feng; Deng, Jianliang; Zhang, Yunlei; Ishikawa, Shintaro; Liu, Yanqing

doi:10.3892/or.2020.7593

Cited by 17 publications

(13 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PARK7 has been identified as a prognostic marker for patients with colorectal cancer, liver cancer, and pancreatic cancer. Patients with high PARK7 expression often have a poor prognosis [ [13] , [14] , [15] ]. Thus, it is interesting to explore the functional role of PARK7 in cervical cancer.…”

Section: Introductionmentioning

confidence: 99%

ROS generation attenuates the anti-cancer effect of CPX on cervical cancer cells by inducing autophagy and inhibiting glycophagy

Xiang

Zhou

et al. 2022

Redox Biology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

ROS generation attenuates the anti-cancer effect of CPX on cervical cancer cells by inducing autophagy and inhibiting glycophagy

Xiang

Zhou

et al. 2022

Redox Biology

View full text Add to dashboard Cite

“…Future applications of our tools will also pave the way to obtain and validate new and improved PARK7 inhibitors, which could potentially serve as new anticancer drugs. Moreover, with the further innovative improvements, our probes can also serve as a diagnostic tool, as PARK7 is a well-known biomarker for various cancers. ,− …”

Section: Discussionmentioning

confidence: 99%

“…Moreover, with the further innovative improvements, our probes can also serve as a diagnostic tool, as PARK7 is a well-known biomarker for various cancers. 16 , 53 − 55 …”

Section: Discussionmentioning

confidence: 99%

Chemical Toolkit for PARK7: Potent, Selective, and High-Throughput

Jia

Kooij

et al. 2022

J. Med. Chem.

View full text Add to dashboard Cite

The multifunctional human Parkinson’s disease protein 7 (PARK7/DJ1) is an attractive therapeutic target due to its link with early-onset Parkinson’s disease, upregulation in various cancers, and contribution to chemoresistance. However, only a few compounds have been identified to bind PARK7 due to the lack of a dedicated chemical toolbox. We report the creation of such a toolbox and showcase the application of each of its components. The selective PARK7 submicromolar inhibitor with a cyanimide reactive group covalently modifies the active site Cys106. Installment of different dyes onto the inhibitor delivered two PARK7 probes. The Rhodamine110 probe provides a high-throughput screening compatible FP assay, showcased by screening a compound library (8000 molecules). The SulfoCy5-equipped probe is a valuable tool to assess the effect of PARK7 inhibitors in a cell lysate. Our work creates new possibilities to explore PARK7 function in a physiologically relevant setting and develop new and improved PARK7 inhibitors.

show abstract

“…The cutoff values of lncRNA 604 and miRNA 564 were calculated by Cutoff Finder (http://molpath.charite.de/cutoff/ index.jsp). We used receiver operator characteristic (ROC) analysis to obtain the cutoff value of the semiquantitative immunoreactivity score (IRS) for ZNF326, as reported elsewhere (19). Figure 6F indicates that IRS 0-4 and IRS 6-12 were classified as low or high expression of ZNF326, respectively.…”

Section: Lncrna 604 Alone or In Combination With Its Regulatory Molec...mentioning

confidence: 99%

LncRNA-ENST00000543604 exerts a tumor-promoting effect via miRNA 564/AEG-1 or ZNF326/EMT and predicts the prognosis of and chemotherapeutic effect in colorectal cancer

et al. 2022

Self Cite

View full text Add to dashboard Cite

ObjectivesColorectal cancer(CRC) is a common malignant tumor. Recent studies have found that lncRNAs play an important role in the occurrence and development of colorectal cancer.MethodsBased on high-throughput sequencing results of fresh CRC tissues and adjacent tissues, we identified lncRNA-ENST00000543604 (lncRNA 604) as the research object by qRT-PCR in CRC tissues and cells. We explored the mechanism of lncRNA 604 action by using luciferin reporter, qRT-PCR and Western blot assays. Kaplan-Meier survival analysis and a Cox regression model were used to analyze the correlation of lncRNA 604 and its regulatory molecules with the prognosis of and chemotherapy efficacy in CRC patients.ResultsIn this study, we found that the expression levels of lncRNA 604 were increased in CRC. LncRNA 604 could promote CRC cell proliferation and metastasis through the miRNA 564/AEG-1 or ZNF326/EMT signaling axis in vivo and in vitro. LncRNA 604 could predict the prognosis of CRC and was an independent negative factor. LncRNA 604 exerted a synergistic effect with miRNA 564 or ZNF326 on the prognosis of CRC. LncRNA 604 could improve chemoresistance by increasing the expression of AEG-1, NF-κB, and ERCC1.ConclusionsOur study demonstrated that lncRNA 604 could promote the progression of CRC via the lncRNA 604/miRNA 564/AEG-1/EMT or lncRNA 604/ZNF326/EMT signaling axis. LncRNA 604 could improve chemoresistance by increasing drug resistance protein expression.

show abstract

DJ‑1 is a new prognostic marker and predicts chemotherapy efficacy in colorectal cancer

Cited by 17 publications

References 34 publications

ROS generation attenuates the anti-cancer effect of CPX on cervical cancer cells by inducing autophagy and inhibiting glycophagy

ROS generation attenuates the anti-cancer effect of CPX on cervical cancer cells by inducing autophagy and inhibiting glycophagy

Chemical Toolkit for PARK7: Potent, Selective, and High-Throughput

LncRNA-ENST00000543604 exerts a tumor-promoting effect via miRNA 564/AEG-1 or ZNF326/EMT and predicts the prognosis of and chemotherapeutic effect in colorectal cancer

Contact Info

Product

Resources

About